Related Experiment Videos
Combined rifampicin and chloramphenicol therapy for Enterobacter osteomyelitis
Postgraduate Medical Journal
|October 1, 1979
Insights
A 2-month-old infant with Enterobacter osteomyelitis, a bone infection, was successfully treated with rifampicin and chloramphenicol. The infant tolerated prolonged rifampicin use without adverse effects, indicating its safety in this context.
Area of Science:
- Pediatric Infectious Diseases
- Neonatal Care
- Pharmacology
Background:
- Osteomyelitis in infants can arise from various sources, including complications from medical interventions.
- Total parenteral nutrition (TPN) is a critical support method for neonates with gastrointestinal issues but may carry infection risks.
- Enterobacter species are opportunistic pathogens that can cause severe infections in vulnerable populations like neonates.
Observation:
- A 2-month-old infant developed Enterobacter osteomyelitis.
- The osteomyelitis complicated the infant's total parenteral nutrition (TPN) regimen.
- The infant was treated with a combination of rifampicin and chloramphenicol.
Findings:
- Successful treatment of Enterobacter osteomyelitis was achieved using rifampicin and chloramphenicol.
- Prolonged administration of rifampicin did not result in any observable adverse side effects.
- This suggests a favorable safety profile for rifampicin in treating infant osteomyelitis.
Implications:
- Rifampicin can be a safe and effective component in the treatment of Enterobacter osteomyelitis in infants.
- This therapeutic approach may be valuable for neonates requiring TPN.
- Further research could explore optimal dosing and duration for rifampicin in similar pediatric cases.
Abstract:
A 2-month-old infant with Enterobacter osteomyelitis complicating total parenteral nutrition was successfully treated with rifampicin and chloramphenicol. No untoward side effects attributed to rifampicin has been noted despite prolonged administration of rifampicin.